Oscar Health Reports Q2 GAAP EPS of -$0.89, Revenue of $2.86B Misses Expectations
ByAinvest
Wednesday, Aug 6, 2025 6:17 am ET1min read
OSCR--
Oscar Health's Q2 performance highlights several challenges, particularly in the Affordable Care Act (ACA) marketplace. The company expects its medical loss ratio (MLR) to rise to 86.8%, up from prior guidance, due to elevated ACA risk scores and utilization trends. This increase in MLR could further erode profitability [3].
Despite the revenue growth of 28.8% year-over-year, investors are concerned about Oscar's ability to maintain its margin path in the face of structural ACA headwinds. The company's MLR in Q1 stood at 75.4%, already above 2024 levels, driven by accruals and risk-adjustment true-ups. Rising morbidity in the ACA single-risk pool and uncertainty around CSR funding create ongoing risks [3].
Investors will closely examine Oscar's Q2 commentary to gauge the company's strategic reset and assess its digital-first model, tight SG&A control, and growing ICHRA/public exchange book. The company's execution risks are high, and restoring investor confidence will be crucial to stem the stock's slide [3].
References:
[1] https://finance.yahoo.com/news/oscar-health-oscr-3-reasons-040126702.html
[2] https://seekingalpha.com/news/4479553-oscar-health-gaap-eps-of-0_89-misses-by-0_01-revenue-of-2_86b-misses-by-60m
[3] https://finance.yahoo.com/news/oscar-health-q2-preview-aca-185625684.html
Oscar Health reported Q2 GAAP EPS of -$0.89, missing estimates by $0.01. Revenue of $2.86B increased 28.8% YoY but missed estimates by $60M.
Oscar Health Inc. (NYSE: OSCR) reported its Q2 2025 earnings, with GAAP EPS of -$0.89, missing estimates by $0.01. Revenue of $2.86 billion increased 28.8% year-over-year but fell short of expectations by $60 million. The company also pre-announced an operating loss of approximately $230 million and a net loss near $228 million, which was significantly below analyst expectations [3].Oscar Health's Q2 performance highlights several challenges, particularly in the Affordable Care Act (ACA) marketplace. The company expects its medical loss ratio (MLR) to rise to 86.8%, up from prior guidance, due to elevated ACA risk scores and utilization trends. This increase in MLR could further erode profitability [3].
Despite the revenue growth of 28.8% year-over-year, investors are concerned about Oscar's ability to maintain its margin path in the face of structural ACA headwinds. The company's MLR in Q1 stood at 75.4%, already above 2024 levels, driven by accruals and risk-adjustment true-ups. Rising morbidity in the ACA single-risk pool and uncertainty around CSR funding create ongoing risks [3].
Investors will closely examine Oscar's Q2 commentary to gauge the company's strategic reset and assess its digital-first model, tight SG&A control, and growing ICHRA/public exchange book. The company's execution risks are high, and restoring investor confidence will be crucial to stem the stock's slide [3].
References:
[1] https://finance.yahoo.com/news/oscar-health-oscr-3-reasons-040126702.html
[2] https://seekingalpha.com/news/4479553-oscar-health-gaap-eps-of-0_89-misses-by-0_01-revenue-of-2_86b-misses-by-60m
[3] https://finance.yahoo.com/news/oscar-health-q2-preview-aca-185625684.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet